Bioventus Company Insiders

BVS Stock  USD 6.26  0.23  3.54%   
Slightly above 75% of Bioventus' corporate insiders are selling. The analysis of insiders' sentiment of trading Bioventus stock suggests that many insiders are alarmed at this time. Bioventus employs about 930 people. The company is managed by 17 executives with a total tenure of roughly 2170 years, averaging almost 127.0 years of service per executive, having 54.71 employees per reported executive.

Insider Sentiment 25

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-04-11Mark Leonard SingletonDisposed 3875 @ 7.57View
2025-03-24Mark Leonard SingletonDisposed 5479 @ 9.79View
2025-03-17Katrina J ChurchDisposed 1018 @ 9.75View
2025-02-18Mark Leonard SingletonDisposed 6498 @ 10.19View
2025-01-13Robert E ClaypooleDisposed 28786 @ 9.1View
2024-12-23Mark Leonard SingletonDisposed 10733 @ 10.53View
2024-08-19John A BartholdsonAcquired 25500 @ 8.55View
2024-08-16John A BartholdsonAcquired 80000 @ 8.55View
Monitoring Bioventus' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

Bioventus' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bioventus' future performance. Based on our forecasts, it is anticipated that Bioventus will maintain a workforce of slightly above 930 employees by August 2025.
 
Covid

Bioventus Management Team Effectiveness

The company has Return on Asset of 0.0333 % which means that on every $100 spent on assets, it made $0.0333 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2024) %, meaning that it generated no profit with money invested by stockholders. Bioventus' management efficiency ratios could be used to measure how well Bioventus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2025. Return On Capital Employed is likely to drop to -0.02 in 2025. At this time, Bioventus' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 568 M in 2025, whereas Other Current Assets are likely to drop slightly above 13.9 M in 2025.
Net Income Applicable To Common Shares is likely to gain to about 23.4 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 62.2 M in 2025.

Bioventus Workforce Comparison

Bioventus is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,405. Bioventus totals roughly 930 in number of employees claiming about 66% of equities under Health Care industry.

Bioventus Profit Margins

The company has Net Profit Margin of (0.06) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.04 %, which entails that for every 100 dollars of revenue, it generated $0.04 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.760.6772
Moderately Up
Very volatile

Bioventus Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioventus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioventus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bioventus insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-06-01
1.4667
22
15
 595,989 
 273,778 
2025-03-01
0.5
7
14
 162,225 
 212,538 
2024-12-01
0.5
3
6
 59,450 
 78,566 
2024-06-01
1.0
31
31
 713,226 
 534,670 
2024-03-01
2.0
14
7
 1,851,750 
 40,850 
2023-09-01
4.5
9
2
 434,994 
 2,604,658 
2023-06-01
2.9286
41
14
 3,480,048 
 144,041 
2023-03-01
0.75
6
8
 86,365 
 80,778 
2022-06-01
0.8333
15
18
 478,162 
 361,924 
2022-03-01
1.45
29
20
 1,478,120 
 460,132 
2021-03-01
1.4167
17
12
 99,615 
 1,858,281 

Bioventus Notable Stakeholders

A Bioventus stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bioventus often face trade-offs trying to please all of them. Bioventus' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bioventus' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Bioventus Management Performance

The success or failure of an entity such as Bioventus often depends on how effective the management is. Bioventus management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bioventus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bioventus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.11)(0.11)
Return On Capital Employed(0.02)(0.02)
Return On Assets(0.05)(0.05)
Return On Equity(0.23)(0.24)
Please note, the imprecision that can be found in Bioventus' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bioventus. Check Bioventus' Beneish M Score to see the likelihood of Bioventus' management manipulating its earnings.

Bioventus Workforce Analysis

Traditionally, organizations such as Bioventus use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bioventus within its industry.

Bioventus Manpower Efficiency

Return on Bioventus Manpower

Revenue Per Employee616.4K
Revenue Per Executive33.7M
Net Loss Per Employee36.1K
Net Loss Per Executive2M
Working Capital Per Employee70.1K
Working Capital Per Executive3.8M

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.